+

WO2001098467A3 - Regulation of human prostasin-like serine protease - Google Patents

Regulation of human prostasin-like serine protease Download PDF

Info

Publication number
WO2001098467A3
WO2001098467A3 PCT/EP2001/007117 EP0107117W WO0198467A3 WO 2001098467 A3 WO2001098467 A3 WO 2001098467A3 EP 0107117 W EP0107117 W EP 0107117W WO 0198467 A3 WO0198467 A3 WO 0198467A3
Authority
WO
WIPO (PCT)
Prior art keywords
human prostasin
regulation
serine protease
reagents
prostasin
Prior art date
Application number
PCT/EP2001/007117
Other languages
French (fr)
Other versions
WO2001098467A2 (en
Inventor
Yonghong Xiao
Vladimir Morozov
Original Assignee
Bayer Ag
Yonghong Xiao
Vladimir Morozov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Yonghong Xiao, Vladimir Morozov filed Critical Bayer Ag
Priority to AU2001266089A priority Critical patent/AU2001266089A1/en
Publication of WO2001098467A2 publication Critical patent/WO2001098467A2/en
Publication of WO2001098467A3 publication Critical patent/WO2001098467A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reagents which regulate human prostasin-like enzyme activity and reagents which bind to human prostasin-like enzyme gene products can be used to regulate human prostasin-like enzyme activity. Such regulation is particularly useful for treating metastasis of malignant cells, tumor angiogenesis, inflammation, chronic obstructive pulmonary disease (COPD), atherosclerosis, neurodegenerative diseases, and pathogenic infections.
PCT/EP2001/007117 2000-06-23 2001-06-22 Regulation of human prostasin-like serine protease WO2001098467A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001266089A AU2001266089A1 (en) 2000-06-23 2001-06-22 Regulation of human prostasin-like serine protease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21358800P 2000-06-23 2000-06-23
US60/213,588 2000-06-23
US27690901P 2001-03-20 2001-03-20
US60/276,909 2001-03-20

Publications (2)

Publication Number Publication Date
WO2001098467A2 WO2001098467A2 (en) 2001-12-27
WO2001098467A3 true WO2001098467A3 (en) 2002-04-04

Family

ID=26908219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007117 WO2001098467A2 (en) 2000-06-23 2001-06-22 Regulation of human prostasin-like serine protease

Country Status (2)

Country Link
AU (1) AU2001266089A1 (en)
WO (1) WO2001098467A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049420B2 (en) 2000-06-23 2006-05-23 Bayer Healthcare Ag Regulation of human prostasin-like serine protease

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106536A2 (en) * 2003-05-28 2004-12-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serine protease 8 (prss8)
US7947436B2 (en) 2004-12-13 2011-05-24 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500344A (en) * 1992-12-03 1996-03-19 The United States Of America As Represented By The Department Of Health And Human Services Serine protease and uses thereof
WO1999046391A2 (en) * 1998-03-12 1999-09-16 Millennium Biotherapeutics, Inc. Prostate derived serine protease (pdsp) protein and nucleic acid molecules and uses therefor
EP1130094A2 (en) * 1999-07-08 2001-09-05 Helix Research Institute Primers for synthesizing full length cDNA clones and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5500344A (en) * 1992-12-03 1996-03-19 The United States Of America As Represented By The Department Of Health And Human Services Serine protease and uses thereof
WO1999046391A2 (en) * 1998-03-12 1999-09-16 Millennium Biotherapeutics, Inc. Prostate derived serine protease (pdsp) protein and nucleic acid molecules and uses therefor
EP1130094A2 (en) * 1999-07-08 2001-09-05 Helix Research Institute Primers for synthesizing full length cDNA clones and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EM_EST EMBL; 14 October 1998 (1998-10-14), NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP), TUMOR GENE INDEX HTTP://WWW.NCBI.NIH.GOV/NCICGAP: "Homo sapiens cDNA clone", XP002183965 *
DATABASE EM_EST EMBL; 21 February 2000 (2000-02-21), NATIONAL CANCER INSTITUTE, CANCER GENOME ANATOMY PROJECT (CGAP), TUMOR GENE INDEX HTTP://WWW.NCBI.NIH.GOV/NCICGAP: "Homo sapiens cDNA clone", XP002183964 *
YU JACK X ET AL: "Molecular Cloning, Tissue-specific Expression, and Cellular Localization of Human Prostasin mRNA.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 22, 1995, pages 13483 - 13489, XP002935257, ISSN: 0021-9258 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049420B2 (en) 2000-06-23 2006-05-23 Bayer Healthcare Ag Regulation of human prostasin-like serine protease

Also Published As

Publication number Publication date
AU2001266089A1 (en) 2002-01-02
WO2001098467A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
WO2001096538A3 (en) Regulation of human transmembrane serine protease
Murphy et al. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases
Ganea et al. Matrix metalloproteinases: useful and deleterious
AU2001259353A1 (en) Novel mutated form of arginine deiminase
Kato et al. Production of trypsins by human gastric cancer cells correlates with their malignant phenotype
Zucker et al. Extraction of type‐IV collagenase/gelatinase from plasma membranes of human cancer cells
WO2002008392A3 (en) Regulation of human matriptase-like serine protease
Oliveira et al. Simplified procedures for the isolation of HF3, bothropasin, disintegrin-like/cysteine-rich protein and a novel PI metalloproteinase from Bothrops jararaca venom
WO2002053146A3 (en) Matrix metalloproteinase inhibitors
O'Mahony et al. Angiostatin generation by human pancreatic cancer
WO2001098467A3 (en) Regulation of human prostasin-like serine protease
Frederick Woessner MMPs and TIMPs: an historical perspective
WO2001096378A3 (en) Human epithin-like serine protease
WO2001098340A3 (en) Regulation of human mast cell protease 6-like enzyme
WO2001098466A3 (en) Regulation of human prostasin-like serine protease
WO2002012461A3 (en) Regulation of human membrane-type serine protease
WO2002026957A3 (en) Regulation of a human serine protease
WO2002024886A3 (en) Regulation of human serine protease
WO2002000702A3 (en) Regulation of human epidermis-specific serine protease
WO2001085959A3 (en) Regulation of human lysostaphin-like protease
WO2008045214A3 (en) Cellulase-free enzyme compositions and host cells for producing the same
WO2001072973A3 (en) Regulation of human heparanase-like enzyme
WO2002018565A3 (en) Regulation of human protein phosphatase iic-like enzyme
WO2001062941A3 (en) Regulation of human gelatinase b-like enzyme 2
del Mar Barbacid et al. Expression and purification of human stromelysin 1 and 3 from baculovirus-infected insect cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载